Polyphase wireless power transfer system achieves 270-kilowatt charge, s...
Scientists at Oak Ridge National Laboratory have demonstrated a direct relationship between climate warming and carbon loss in a peatland ecosystem.
Five researchers at the Department of Energy’s Oak Ridge National Laboratory have been named ORNL Corporate Fellows in recognition of significant career accomplishments and continued leadership in their scientific fields.
A team of researchers has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease — the enzyme that enables the virus to reproduce.
Oak Ridge National Laboratory has launched a program designed to accelerate deployment of innovations that may help fight the COVID-19 pandemic. The COVID-19 Rapid Access Licensing Program will allow companies to license these select technologies at no cost for one year.
UT-Battelle, the managing contractor of Oak Ridge National Laboratory for the U.S. Department of Energy, has donated $10,000 to Second Harvest Food Bank of East Tennessee, providing 30,000 meals for those in need.
Researchers at the Department of Energy’s Oak Ridge National Laboratory have used Summit, the world’s most powerful and smartest supercomputer, to identify 77 small-molecule drug compounds that might warrant further study in the fight
A team of scientists led by Oak Ridge National Laboratory found that while all regions of the country can expect an earlier start to the growing season as temperatures rise, the trend is likely to become more variable year-over-year in hotter regions.
A technology developed at the ORNL and scaled up by Vertimass LLC to convert ethanol into fuels suitable for aviation, shipping and other heavy-duty applications can be price-competitive with conventional fuels
ORNL and The University of Toledo have entered into a memorandum of understanding for collaborative research.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.